文献速递呼吸道感染呼吸危重症与机械通气

重症肺炎炎症表型:从临床证据到小鼠模型的精准治疗研究

Inflammatory phenotypes in severe pneumonia: clinical evidence to mouse models for precision therapeutics.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

该研究在548例肺部脓毒症ICU患者中通过潜类别分析识别出高炎症和低炎症两种表型,高炎症表型肺损伤更重且死亡率更高。研究建立肺炎链球菌肺炎小鼠模型复现了两种表型,发现抗炎治疗(地塞米松和IL-6受体阻断)仅对炎症更重的小鼠亚组有效,为表型靶向治疗提供转化框架。

要点

  • 肺部脓毒症患者可识别高炎症与低炎症两种表型,高炎症表型肺损伤更重、死亡率更高
  • 小鼠肺炎模型复现两种炎症表型且轨迹不同
  • 抗炎治疗获益仅见于炎症更重的小鼠亚组

核心结论

  • 重症肺炎(肺部脓毒症)存在生物标志物定义的高炎症和低炎症表型,高炎症表型预后更差。
  • 在肺炎小鼠模型中复现了两种表型,抗炎干预的获益仅见于炎症更重的亚组。
  • 该研究为重症肺炎表型靶向治疗提供了从临床到动物模型的转化研究框架。

研究设计与样本

  • 对548例ICU肺部脓毒症患者队列进行潜类别分析(LCA)识别炎症表型,并用验证过的分类器模型检验表型与临床结局的关联。
  • 建立肺炎链球菌肺炎小鼠模型,复现患者表型的关键特征,并测试对地塞米松和IL-6受体阻断的反应。

主要发现

  • 在肺部脓毒症患者中识别出两种表型:高炎症表型肺损伤更重且死亡率增加,低炎症表型结局更有利。
  • 尽管病原暴露和基线条件一致,小鼠中LCA仍识别出两种表型,且肺损伤和死亡率轨迹不同。
  • 抗炎干预的治疗获益仅见于炎症更重的小鼠。

临床怎么用

  • 对重症肺炎患者可考虑基于生物标志物进行炎症表型分型,以识别可能从抗炎治疗中获益的高炎症亚组。
  • 抗炎治疗(如地塞米松或IL-6受体阻断)的获益可能仅限于炎症更重的表型,需表型指导用药。

局限性

  • 小鼠模型虽复现患者表型关键特征,但动物结果向临床转化仍需进一步验证。
  • 研究未报告表型分类器的具体生物标志物阈值及干预剂量等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Hyperinflammatory and hypoinflammatory phenotypes previously identified in sepsis and acute respiratory distress syndrome may enable precision therapies, but their clinical relevance and translational modeling in severe pneumonia remain incompletely characterized. OBJECTIVES: To examine biomarker-defined hyperinflammatory and hypoinflammatory phenotypes in critically ill patients with pneumonia (pulmonary sepsis), test whether the biomarkers that define these phenotypes identify subgroups and outcomes in a mouse model of bacterial pneumonia, and determine whether the mouse phenotypes respond differently to therapeutic interventions. METHODS: We performed latent class analysis (LCA) in a cohort of 548 ICU patients with pulmonary sepsis to identify inflammatory phenotypes and test the association of these phenotypes with clinical outcomes using validated classifier models. We developed a mouse model of pneumococcal pneumonia that recapitulated key aspects of these phenotypes and tested responses to dexamethasone and IL-6 receptor blockade. MEASUREMENTS AND MAIN RESULTS: Two phenotypes were identified in patients with pulmonary sepsis: a hyperinflammatory phenotype with more lung injury and increased mortality, and a hypoinflammatory phenotype with more favorable outcomes. Despite uniform pathogen exposure and baseline conditions, LCA identified 2 phenotypes in the mice with divergent trajectories (lung injury and mortality). Therapeutic benefit from anti-inflammatory interventions was observed exclusively in the more inflamed mice. CONCLUSIONS: By integrating clinical data from human studies and experimental findings in a clinically relevant mouse model, this study provides a translational framework for developing phenotype-targeted therapies for critical illness, with the goal of improving patient outcomes.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Taenaka H, Evrard B, Maishan M, et al. Inflammatory phenotypes in severe pneumonia: clinical evidence to mouse models for precision therapeutics. Am J Respir Crit Care Med. 2026. PMID: 42535902. doi:10.1093/ajrccm/aamag402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。